Pacific Biosciences of California (NASDAQ:PACB) cut its full-year revenue outlook on Friday after reporting second-quarter revenue of $39 million, as the company navigates a slower-than-expected transition to its SPRQ-Nx sequencing chemistry and works to rein in costs. CFO Jim Gibson outlined the revised guidance during the Canaccord Genuity Growth Conference on August 16, 2026, citing a “slight lull” in Q2 consumables orders as customers used up existing inventory before reordering the new chemistry.
SPRQ-Nx Transition and Cost Pressures Shape Near-Term Results
PacBio commercially launched SPRQ-Nx in May, but adoption has been uneven. The chemistry enables three uses per chip and carries an average selling price roughly 35% below the prior offering. While about one-third of customers have converted their software to enable the multi-use workflow, Gibson said some larger service providers are still working through existing stock. He estimated each Revio system would need to run 10 to 15 additional samples per month to return to revenue parity after the price reduction.
Also read: Bank of Hawaii (BOH) Ex-Dividend Date Approaching: A Look at the 'Dividend Run' Pattern
The slower conversion coincides with rising compute and memory costs, prompting PacBio to announce a targeted reduction in force. The restructuring, which Gibson said substantially reduced marketing functions and removed management layers, is expected to cut compensation and benefits expenses by $15 million to $20 million. The company also anticipates reducing spending by another $30 million to $40 million in 2027 as it completes major investment in a new high-throughput sequencing platform.
Leadership Transition and Strategic Priorities
Mark Van Oene has officially taken over as chief executive officer, succeeding the previous leadership team. Van Oene, who joined PacBio about five years ago, previously led research and development and operations, and was involved in the launches of the Revio and Vega systems as well as the SPRQ-Nx chemistry. Gibson said Van Oene’s priorities include expanding PacBio’s clinical presence and building on growth in Europe, the Middle East and Africa (EMEA), where the company reported more than 50% year-over-year growth.
Also read: Stocks Close Lower as Weak Retail Sales, Consumer Sentiment Fuel Economic Worries
That regional strength is supported by rare-disease testing, favorable reimbursement for whole-genome sequencing, and the fit of Revio’s throughput at smaller hospitals and single-payer healthcare systems. In the U.S., Gibson said larger centralized testing labs are seeking higher-throughput systems and favorable reimbursement conditions for whole-genome sequencing.
Clinical Growth and Population Genomics Pipeline
Despite the near-term headwinds, PacBio highlighted 67% growth in its clinical business, with clinical consumables representing a mid-teens percentage of total consumables revenue. The company also signed two fleet-expansion agreements with existing customers and secured a new population genomics initiative that received five Revio systems. Gibson said details on that initiative would be shared in the third quarter.
PacBio’s largest project to date remains a 100,000-sample collaboration with GeneDx, which Gibson said was won through a competitive process where customers prioritized data depth, coverage, and reproducibility. He noted that researchers and clinical organizations are increasingly interested in generating more complete genomic data sets upfront rather than enriching short-read data later. Large projects enabled by SPRQ-Nx are expected to become more meaningful contributors to revenue in 2027, as installations and project ramps typically take four to six months.
Path to Cash-Flow Positivity
PacBio’s path to cash-flow positivity in 2028 depends on several factors: successfully launching its ultra-high-throughput platform as a portfolio addition, improving compute and DRAM economics, and converting a majority of customers to SPRQ-Nx. Gibson said the company would need to be “knocking on the door of 50%” gross margin to support that objective.
The company has been buying inventory to secure supply for the remainder of the year, but Gibson said he expects to be past much of the major spending for the new platform by 2027. The new system is intended to improve price parity with short-read sequencing, support larger data sets, and give customers more flexibility over compute requirements.
For investors, the revised outlook underscores the execution risks inherent in a chemistry transition, but also highlights the potential upside if sample volumes accelerate and the new platform lands as planned. The next few quarters will be critical in determining whether PacBio can convert its pipeline of population-scale projects into sustained revenue growth.
This article is for informational purposes only and does not constitute financial advice. The stock market is volatile, and investors should conduct their own research or consult a financial advisor before making investment decisions.
